INmune Bio (NASDAQ: INMB) is a clinical-stage immunology company with drug programs focused on harnessing the innate immune system to treat cancer, Alzheimer’s disease and NASH.

INmune Bio Inc. (NASDAQ: INMB) - a diversified, clinical stage immunology company developing novel therapies targeting distinct parts of a patient’s innate immune system to fight disease. Drug candidates, INKmune™ and INB03, may be used to treat cancer. XPro1595 targets neuroinflammation as a cause of Alzheimer’s disease and NeuLiv™ targets nonalcoholic steatohepatitis (NASH). INmune Bio’s product platforms utilize a precision therapy approach, promoting the body’s innate immune response to treat unsolved problems in medicine.

Multiple Programs in Clinical Trials:

**What is the innate immune system?** Our body’s immune system is broken into two components, innate and adaptive. **Innate** and **Adaptive** immune system. The Adaptive immune system is T and B cells. The Innate immune system is myeloid and NK cells. The Innate and Adaptive immune system must work together to battle disease. INMB is focused exclusively on cells on the Innate immune system including HSC, MDSC,NK, and microglial cells.

**INB03**
- Targets Myeloid-Derived Suppressor Cells (MDSC) that can inhibit anti-tumor immune reactions and stimulate tumor growth
- Resistance to immunotherapy is a fast-growth oncology market

**INKmune™**
- Biologic therapy that primes NK cells to eliminate minimal residual disease – a major cause of cancer relapse and death
- First trials in women with relapsed/refractory ovarian cancer

**XPro1595**
- Targeting activated microglial cells that cause neuroinflammation – a cause of brain cell loss and synaptic dysfunction in AD
- Alzheimer’s disease/dementia market - 50 million people worldwide
- Awarded $1 million grant from Alzheimer’s Association

**NeuLiv™**
- Targeting chronic inflammation caused by innate immune cells as the cause of hepatocyte death fibrosis.

**Significant Upcoming Catalysts**

<table>
<thead>
<tr>
<th>Product</th>
<th>Geography</th>
<th>Indication</th>
<th>Event</th>
<th>Timeline</th>
</tr>
</thead>
<tbody>
<tr>
<td>INB03</td>
<td>Australia</td>
<td>Solid Tumors</td>
<td>Reported Positive Preliminary Data from Phase I</td>
<td>August ’19</td>
</tr>
<tr>
<td>INKmune</td>
<td>UK</td>
<td>Ovarian Cancer</td>
<td>Initiate Enrollment of Phase 1/2 study</td>
<td>2H’20</td>
</tr>
<tr>
<td>INB03</td>
<td>Australia</td>
<td>Solid Tumors</td>
<td>Initiate INB03 Combination Phase 2 Study in Cancer</td>
<td>1H ’20</td>
</tr>
<tr>
<td>XPro1595</td>
<td>Australia</td>
<td>Alzheimer’s</td>
<td>Initiate Enrollment of Phase 1 Study</td>
<td>Q4‘19</td>
</tr>
<tr>
<td>NeuLiv</td>
<td>Australia</td>
<td>NASH</td>
<td>Initiate NeuLiv Phase II Nash trial</td>
<td>1H ’20</td>
</tr>
<tr>
<td>XPro1595</td>
<td>Australia</td>
<td>Alzheimer’s</td>
<td>Early Data</td>
<td>2H’20</td>
</tr>
<tr>
<td>INB03</td>
<td>Australia/US</td>
<td>Solid Tumors</td>
<td>Initiate INB03 combination immunotherapy Phase 2 Study</td>
<td>1H ’20</td>
</tr>
</tbody>
</table>
NeuLiv targets the Three Cycles of Innate Inflammation that can cause NASH

In murine models of NAFLD and NASH, NeuLiv decreases insulin resistance, hepatic steatosis, hepatocyte ballooning and fibrosis.

INMB is designing a Phase II POC trial in patients with NASH

INB03 Development Program

Completed Phase 1 Open-Label, Dose-Escalation Trial
11 patients with advanced solid tumors with biomarkers of inflammation
- 3 dose levels of INB03 sub-cutaneous once a week
- All goals met: 1) safe and well tolerated; 2) Phase II dose defined; 3) pharmacodynamic effect demonstrated

Phase 2 Combination Trial in Patients with Cancer
Proof-of-Concept trial of INB03+Immunotherapy
- Treatment: Immunotherapy verses INB03+immunotherapy
- Endpoints: Improved efficacy in combination therapy arm.

Xpro1595 targets neuroinflammation and microglial activation that can cause nerve cell death and synaptic dysfunction that can lead to cognitive decline of AD and dementia
Phase 1: Biomarker directed trial of patients with inflammation and proven Alzheimer’s disease
18 patients in 3 dosing cohorts
- Weekly XPro1595 subQ for 3 months
- Biomarkers of inflammation at 0, 6 and 12 weeks
- Endpoints:
  - Safety
  - Decreased inflammation blood, cerebrospinal fluid (CSF), brain (white matter free water by MRI) and breath (breath volatile organic compounds)
  - Measures of cogitation, psychiatric symptoms and quality of life (QOL)

XPro1595 targets neuroinflammation and microglial activation that can cause nerve cell death and synaptic dysfunction that can lead to cognitive decline of AD and dementia
Phase 1: Biomarker directed trial of patients with inflammation and proven Alzheimer’s disease
18 patients in 3 dosing cohorts
- Weekly XPro1595 subQ for 3 months
- Biomarkers of inflammation at 0, 6 and 12 weeks
- Endpoints:
  - Safety
  - Decreased inflammation blood, cerebrospinal fluid (CSF), brain (white matter free water by MRI) and breath (breath volatile organic compounds)
  - Measures of cogitation, psychiatric symptoms and quality of life (QOL)

INKmune: Targets Minimal Residual Disease (MRD**)
Residual disease is the cancer that is left behind after treatment; two types – overt (visible by imaging studies) and minimal (MRD** – NOT visible by imaging studies)

NK cells are responsible for eliminating MRD**, problem is patient’s NK cells are inactive. INKmune primes the NK cells to kill the cancer. If MRD is eliminated, the patient should not relapse

Phase 1/2 study in relapsed/refractory CaOva
- Platinum resistant/refractory patients with minimal residual disease
- Treatment: INKmune - 6 doses
- Endpoints: Safety, increased NK activation and tumor killing and decreased tumor burden (when in Phase 2)

Information about Forward-Looking Statements

This fact sheet may contain forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Words such as “anticipate,” “estimate,” “expect,” “intend,” “plan,” “project” and other similar words and expressions are intended to signify forward-looking statements. Forward-looking statements are not guarantees of future results and conditions but rather are subject to various risks and uncertainties.

Some of these risks and uncertainties are identified in the company's filings with the SEC. The occurrence of any of these risks and uncertainties could have a material adverse effect on the company’s business, financial condition, and results of operations.

For additional disclosure regarding risks faced by INmune Bio, Inc., please see our public filings with the Securities and Exchange Commission, available on the Investors section of the website at www.INmuneBio.com and the SEC’s website at www.SEC.gov.